Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma

In conclusion, a fixed-dose regimen of tezepelumab 210 mg subcutaneously Q4W is appropriate for eligible adults and adolescents with severe, uncontrolled asthma.PMID:38632826 | DOI:10.1002/jcph.2433
Source: The Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research